Exagen (NASDAQ:XGN) Issues Earnings Results

Exagen (NASDAQ:XGN) released its earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative net margin of 30.36% and a negative return on equity of 84.26%. The company had revenue of $12.51 million for the quarter, compared to analysts’ expectations of $13.55 million. During the same quarter last year, the business earned ($0.31) EPS. Exagen updated its FY 2024 guidance to EPS.

Exagen Price Performance

NASDAQ XGN traded up $0.05 on Wednesday, hitting $2.84. 11,178 shares of the stock were exchanged, compared to its average volume of 41,810. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13. The stock has a fifty day moving average price of $2.84 and a two-hundred day moving average price of $2.37. Exagen has a 52-week low of $1.30 and a 52-week high of $3.71.

Wall Street Analysts Forecast Growth

Separately, William Blair reaffirmed an “outperform” rating on shares of Exagen in a report on Wednesday.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).